Use of Dengvaxia® in Australian travellers: a case series.

This article discusses the use of the Dengvaxia® vaccine in Australian travelers. Dengue fever is a mosquito-borne viral disease that can cause severe complications. Dengvaxia® is a live recombinant tetravalent dengue vaccine that was licensed in Mexico in 2015 and has since been approved in over 20 countries. In Australia, Dengvaxia® is recommended for long-term travelers aged 9-45 years who have had previous dengue infection and plan to reside in highly dengue-endemic regions. However, its use in Australia has been limited due to strict criteria and high cost. A case series of seven travelers who received Dengvaxia® at a travel medicine clinic in Brisbane found that the vaccine was well-tolerated, with only mild to moderate adverse events reported. It is important to note that most travelers from non-endemic countries should not receive Dengvaxia® as they are seronegative and may be at risk of severe dengue. While another dengue vaccine, Qdenga®, is available in some countries, Dengvaxia® remains the only option for Australian travelers at present. The study acknowledges its limitations, including the small sample size and the fact that it represents the experience of one clinic. Overall, Dengvaxia® has been rarely used in Australia but may be considered in certain circumstances. [Extracted from the article]